Noradrenergic and specific serotonergic antidepressant: Difference between revisions

Browse history interactively Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 23:38, 20 December 2004 editSchneelocke (talk \| contribs)Extended confirmed users11,221 edits Initial stub. This contains a lot of "thought to" and "said to"; maybe someone with a medical background can provide info on results of studies etc.?		Revision as of 04:14, 23 March 2005 edit undoCeyockey (talk \| contribs)Administrators83,213 editsmNo edit summaryNext edit →
Line 15:		Line 15:
	*		*

	{{~~med~~-stub}}		{{treatment-stub}}
	]		]

Revision as of 04:14, 23 March 2005

Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.

Examples of NaSSAs include:

Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)

NaSSAs are said to have fewer side-effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with NaSSAs.

Also see

Clinical depression

External links

J. Fawcett, R. L. Barkin: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression

This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: